ERBB2 and breast carcinoma: Meanwhile, DESTINY-Breast11 (NCT05113251), in the neoadjuvant setting, compares the efficacy of T-DXd monotherapy with the subsequent use of THP and ddAC-THP in high-risk HER2-positive early-stage breast cancer patients.